Synexus sets sights on US market

SYNEXUS, a north west firm which recruits patients for trials of drugs to treat cancer, obesity, diabetes, osteoporosis and other conditions, increased operating profits by 50 per cent in the first half of the financial year and underlined its ambitions to enter the US market.

SYNEXUS, a north west firm which recruits patients for trials of drugs to treat cancer, obesity, diabetes, osteoporosis and other conditions, increased operating profits by 50 per cent in the first half of the financial year and underlined its ambitions to enter the US market.

Turnover in the six months to September 30 grew 49 per cent to é5.2m and profits came in at é380,000, up from é250,000. Synexus is based in Chorley and has two sites in Greater Manchester.

The AIM-listed company operates from 14 locations in six countries and is looking to make more acquisitions following swoops in Poland and Hungary earlier this year. It has a confirmed order book of é15.7m with clients such as AstraZeneca, Novartis, Pfizer and Bayer.